AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

Several launches in 2027 (Amgen, Altimmune), 2028 (Pfizer, Roche, Viking, and Structure), and 2029 (Roche, Viking, ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...

"Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I" was originally created and published by ...

Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more ...